NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
CHILDREN'S ALLEGRA ALLERGY (fexofenadine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose sneezing itchy, water eyes itching of the nose and 1 more indications. First approved in 2007.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Children's Allegra Allergy is an orally disintegrating tablet containing fexofenadine hydrochloride, a second-generation antihistamine approved in 2007. It treats symptoms of hay fever and upper respiratory allergies including runny nose, sneezing, itchy/watery eyes, and throat itching. The drug works as a selective H1-receptor antagonist to reduce allergic inflammation in pediatric patients.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating defensive positioning and potential workforce realignment for brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ALLEGRA ALLERGY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.